Virax Biolabs Group Limited(VRAX)

Biotechnology · Lanarkshire, SC

$1.92-0.48 (-20.00%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T19:54:26.684Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:54:26.684Z.

Quote observation: 2026-10-06T19:50:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 358,320
TTM revenue · period ending 2026-03-31: N/A

FMP input reference: 76ce780248c1f493ccbdb0751af92273333f1ee075484263629f1dd5eb2dbf7e

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VRAX PS Ratio Metrics

PS RATIO

N/A

VRAX Competitors' PS Ratio

VRAX

Virax Biolabs Group Limited

Current

Market Cap

$358320.00

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NIKI

Niki BioSolutions, Inc.

vs VRAX

Market Cap

$401484.00

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPRC

SciSparc Ltd.

vs VRAX

Market Cap

$246973.00

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XRTX

XORTX Therapeutics Inc.

vs VRAX

Market Cap

$479001.00

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VIVS

VivoSim Labs, Inc.

vs VRAX

Market Cap

$527596.00

PS Ratio

4.71

TTM Avg

17.12

3Y Avg

18.70

5Y Avg

18.70

HCWB

HCW Biologics Inc.

vs VRAX

Market Cap

$566203.00

PS Ratio

0.08

TTM Avg

5.16

3Y Avg

225.96

5Y Avg

406.71

SLXN

Silexion Therapeutics Ltd.

vs VRAX

Market Cap

$108771.00

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBM

Psyence Biomedical Ltd.

vs VRAX

Market Cap

$96046.00

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRFX

PRF Technologies Ltd.

vs VRAX

Market Cap

$70868.00

PS Ratio

1.79

TTM Avg

236.43

3Y Avg

15964481498759.19

5Y Avg

12825398057992.62

AKAN

Akanda Corp.

vs VRAX

Market Cap

$61172.00

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Virax Biolabs Group Limited (VRAX)	$358320.00	N/A	N/A	N/A	N/A
Niki BioSolutions, Inc. (NIKI)vs ›	$401484.00	N/A	N/A	N/A	N/A
SciSparc Ltd. (SPRC)vs ›	$246973.00	N/A	N/A	N/A	N/A
XORTX Therapeutics Inc. (XRTX)vs ›	$479001.00	N/A	N/A	N/A	N/A
VivoSim Labs, Inc. (VIVS)vs ›	$527596.00	4.71	17.12	18.70	18.70
HCW Biologics Inc. (HCWB)vs ›	$566203.00	0.08	5.16	225.96	406.71
Silexion Therapeutics Ltd. (SLXN)vs ›	$108771.00	N/A	N/A	N/A	N/A
Psyence Biomedical Ltd. (PBM)vs ›	$96046.00	N/A	N/A	N/A	N/A
PRF Technologies Ltd. (PRFX)vs ›	$70868.00	1.79	236.43	15964481498759.19	12825398057992.62
Akanda Corp. (AKAN)vs ›	$61172.00	N/A	N/A	N/A	N/A

How this was calculated

Half-year reporter: no trailing two-half-year basis, because the half-year figures cannot be checked against the annual report: the newest completed fiscal year's annual revenue and net income are both below 25 million, too small to compare.

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

VRAX PS Ratio Metrics

VRAX Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics